While the majority of PBMC samples belonged to patients with AML (Supplementary Table S4), the cytotoxic effect was also demonstrated in other diagnoses and was independent of blast percentage (Supplementary Figure S12), supporting the evidence that HA-1 is a universal hematological target suitable for immunotherapy of a broad range of hematological malignancies. Here, ARHGAP45 is linked to hematologic disorder.